181 related articles for article (PubMed ID: 24474638)
1. Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Xiong Y; Xu A; Zhou JP; Tang J; Zhang ZL; Zhou HH; Zhang W; Chen XP
Int J Hematol; 2014 Mar; 99(3):263-71. PubMed ID: 24474638
[TBL] [Abstract][Full Text] [Related]
2. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
3. Identification of
Xiang Q; Ji SD; Zhang Z; Zhao X; Cui YM
Biomed Res Int; 2016; 2016():5675084. PubMed ID: 27965976
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Storey RF; Melissa Thornton S; Lawrance R; Husted S; Wickens M; Emanuelsson H; Cannon CP; Heptinstall S; Armstrong M
Platelets; 2009 Aug; 20(5):341-8. PubMed ID: 19637098
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
Thromb Haemost; 2013 Oct; 110(4):769-76. PubMed ID: 23903326
[TBL] [Abstract][Full Text] [Related]
6. No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.
Li M; Hu Y; Li H; Wen Z; Hu X; Zhang D; Zhang Y; Xiao J; Tang J; Chen X
Biol Pharm Bull; 2017; 40(1):88-96. PubMed ID: 28049954
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
Liu S; Xue L; Shi X; Sun Z; Zhu Z; Zhang X; Tian X
Eur J Clin Pharmacol; 2018 Jun; 74(6):745-754. PubMed ID: 29442148
[TBL] [Abstract][Full Text] [Related]
8. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.
Hobl EL; Derhaschnig U; Firbas C; Schoergenhofer C; Schwameis M; Jilma B
Eur J Clin Invest; 2013 Dec; 43(12):1258-61. PubMed ID: 24112116
[TBL] [Abstract][Full Text] [Related]
9. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease.
Kunicki TJ; Williams SA; Nugent DJ; Harrison P; Segal HC; Syed A; Rothwell PM
Thromb Haemost; 2009 Jan; 101(1):123-33. PubMed ID: 19132198
[TBL] [Abstract][Full Text] [Related]
10. Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers.
Li M; Hu Y; Wen Z; Li H; Hu X; Zhang Y; Zhang Z; Xiao J; Tang J; Chen X
Xenobiotica; 2017 Dec; 47(12):1130-1138. PubMed ID: 27937053
[TBL] [Abstract][Full Text] [Related]
11. Novel mutations of integrin αIIb and β3 genes in Turkish children with Glanzmann's thrombasthenia.
Tokgoz H; Torun Ozkan D; Caliskan U; Akar N
Platelets; 2015; 26(8):779-82. PubMed ID: 25734216
[TBL] [Abstract][Full Text] [Related]
12. Linkage disequilibrium amongst ITGA2B and ITGB3 gene variants in patients with Glanzmann thrombasthenia confirms that most disease-causing mutations are recent.
Pillois X; Nurden AT
Br J Haematol; 2016 Nov; 175(4):686-695. PubMed ID: 27469266
[TBL] [Abstract][Full Text] [Related]
13. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.
Fontana P; Dupont A; Gandrille S; Bachelot-Loza C; Reny JL; Aiach M; Gaussem P
Circulation; 2003 Aug; 108(8):989-95. PubMed ID: 12912815
[TBL] [Abstract][Full Text] [Related]
14. Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
Baos S; Underwood W; Culliford L; Reeves BC; Rogers CA; Bowles R; Johnson T; Baumbach A; Mumford A
Trials; 2017 Nov; 18(1):529. PubMed ID: 29121979
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.
Teng R; Butler K
Eur J Clin Pharmacol; 2010 May; 66(5):487-96. PubMed ID: 20091161
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations.
Sandrock-Lang K; Oldenburg J; Wiegering V; Halimeh S; Santoso S; Kurnik K; Fischer L; Tsakiris DA; Sigl-Kraetzig M; Brand B; Bührlen M; Kraetzer K; Deeg N; Hund M; Busse E; Kahle A; Zieger B
Thromb Haemost; 2015 Apr; 113(4):782-91. PubMed ID: 25373348
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
Butler K; Teng R
Br J Clin Pharmacol; 2010 Jul; 70(1):65-77. PubMed ID: 20642549
[TBL] [Abstract][Full Text] [Related]
18. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population.
Kim KA; Song WG; Lee HM; Joo HJ; Park JY
Thromb Res; 2013 Aug; 132(2):221-6. PubMed ID: 23849096
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine identifies a pathogenic variant of the ITGA2B gene responsible for Glanzmann's thrombasthenia in a cat.
Li RHL; Ontiveros E; Nguyen N; Stern JA; Lee E; Hardy BT;
J Vet Intern Med; 2020 Nov; 34(6):2438-2446. PubMed ID: 32935881
[TBL] [Abstract][Full Text] [Related]
20. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
